Sciele Pharma, Inc., a Shionogi company, and Addrenex Pharmaceuticals today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD). In multi-center, placebo-controlled, double-blind, randomized Phase III clinical trials, Clonicel showed statistical significance when used to treat ADHD.
Ed Schutter, President and Chief Operating Officer of Sciele Pharma, said, “We are pleased that Addrenex has filed the sNDA with the FDA. Clonicel is an important product in our pediatric pipeline, and we are excited about the potential benefit that Clonicel may provide to children and adolescents who have ADHD.”
Moise Khayrallah, PhD, Chief Executive Officer of Addrenex Pharmaceuticals, said, “Clonicel was designed to normalize excess adrenergic hormones that may cause symptoms of ADHD. In phase III clinical trials, Clonicel demonstrated an improvement in an aggregate of 18 ADHD symptoms recognized by the American Psychiatric Association and used by doctors to diagnose and classify ADHD in children and adolescents.”
In July 2007, Sciele signed an exclusive licensing agreement with Addrenex to market its modified-release formulation of clonidine hydrochloride for the treatment of ADHD and hypertension in the United States, Mexico and Canada.
Experts recommend cascade screening over universal lipid screening for familial hypercholesterolemia